KR890010202A - 사람 단백질 c의 지모겐 형태의 발현용 벡터 및 화합물 - Google Patents
사람 단백질 c의 지모겐 형태의 발현용 벡터 및 화합물 Download PDFInfo
- Publication number
- KR890010202A KR890010202A KR1019880017552A KR880017552A KR890010202A KR 890010202 A KR890010202 A KR 890010202A KR 1019880017552 A KR1019880017552 A KR 1019880017552A KR 880017552 A KR880017552 A KR 880017552A KR 890010202 A KR890010202 A KR 890010202A
- Authority
- KR
- South Korea
- Prior art keywords
- pro
- asp
- sequence
- phe
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 title claims 7
- 101500025568 Homo sapiens Saposin-D Proteins 0.000 title claims 6
- 150000001875 compounds Chemical class 0.000 title claims 6
- 229940100689 human protein c Drugs 0.000 title claims 6
- 239000013612 plasmid Substances 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 16
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 239000004472 Lysine Substances 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- 101800004937 Protein C Proteins 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 101800001700 Saposin-D Proteins 0.000 claims 4
- 102400000827 Saposin-D Human genes 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 235000013922 glutamic acid Nutrition 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 4
- 229960000310 isoleucine Drugs 0.000 claims 4
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 229930182817 methionine Natural products 0.000 claims 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- 229960000856 protein c Drugs 0.000 claims 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- 108010016626 Dipeptides Proteins 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108020004511 Recombinant DNA Proteins 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108010062796 arginyllysine Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002439 hemostatic effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 1
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 claims 1
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 claims 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 108010068380 arginylarginine Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims 1
- 108010087823 glycyltyrosine Proteins 0.000 claims 1
- 108010054155 lysyllysine Proteins 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 238000010276 construction Methods 0.000 description 4
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 4개의 부분으로 구성되며, 출발 플라스미드 pLAPC의 작제(construction)에 사용되는 출발물질인 플라스미드 pLPC에 대한 작제방법을 도식적으로 나타낸 것이다, 제1도, 부분 A는 BK 바이러스 및 플라스미드 pdBPV-MMTneo로부터 플라스미드 pBKneol의 작제를 설명한다. 제1도, 부분 B는 아데노바이러스 2 및 플라스미드 pSV2cat로부터 플라스미드 pLPcat의 작제를 설명한다.
Claims (27)
- 아미노 말단으로부터 카복시 말단까지, a) γ -카복실화되고, 분비된 단백질의 시그날 펩티드 및 프로펩티드 ; b) 사람 단백질 C의 경 쇄(light chain) ; c) 디펩티드 리진-아르기닌, 아르기닌-리진, 리진-리진, 또는 아르기닌-아르기닌 ; 및 d) 하기의 아미노산 잔기 서열을 함유하는 단백질에 대한 암호와 서열을 함유함을 특징으로 하는 DNA 화합물.상기 서열에서, R1은 PHE, GLY, TYR 또는 TRP이고, R2는 VAL 또는 PRO이며, R3는 ASP 또는 ASN이고, ARG는 아르기닌이며, ASN은 아스파라긴이고, ASP는 아스파르트산이며, -COOH는 카복시 말단이고, CYS는 시스테인이며, GLN은 글루타민이고, GLU는 글루탐산이며, GLY는 글리신이고, HIS는 히스티딘이며, ILE는 이소로이신이고, LEU는 로이신이며, LYS는 리진이고, MET는 메티오닌이며, PHE는 페닐알라닌이고, PRO는 프롤린이며, SER는 세린이고, THR는 트레오닌이며, TRP는 트립토판이고, TYR은 티로신이며, VAL은 발린이다.
- 제1항에 있어서, 시그날 펩티드 및 프로펩티드가 초기 사람 단백질 C의 시그날 펩티드 및 프로펩티드인 DNA 화합물.
- 제1항 또는 2항에 있어서, 디펩티드가 리진-아르기닌인 DNA 화합물.
- 제3항에 있어서, DNA에 의해 암호화된 폴리펩티드가 하기와 같은 DNA 화합물.상기 서열에서, -H2N은 아미노 말단이고, R1은 PHE, GLY TYR 또는 TRP이며, R2는 PRO 또는 VAL 이고, R3는 ASP 또는 ASN이다.
- 제1항, 2항, 3항 또는 4항의 DNA 화합물을 함유함을 특징으로 제조합 DNA 발현 벡터.
- 제5항에 있어서, R1이 PHE이고, R2가 PRO이며, R3가 ASP인 벡터.
- 제6항에 있어서, 플라스미드 pLPC-167F인 벡터.
- 제5항에 있어서, R1이 GLY이고, R2가 PRO이며, R3가 ASP인 벡터.
- 제8항에 있어서, 플라스미드 pLPC-167G인 벡터.
- 제5항의 벡터로 형질전환된 진핵 숙주 세포.
- 제10항에 있어서, 293/pLPC-167F인 진핵 숙주 세포.
- 제10항에 있어서, 293/pLPC-167G인 진핵 숙주 세포.
- 제10항에 있어서, AV12/pLPC-167F인 진핵 숙주 세포.
- 제10항에 있어서, AV12/pLPC-167G인 진핵 숙주 세포.
- (A) (i) 아미노 말단으로부터 카복시 말단까지, a)- 카복실화되고, 분비된 단백질의 시그날 펩티드 및 프로-펩티드 ; b) 사람 단백질 C의 경 쇄 ; c) 디펩티드 LYS-ARG, ARG-LYS, LYS-LYS 또는 ARG-ARG ; 및 d) 하기 아미노산 잔기 서열을 함유하는 아미노산 잔기 서열을 암호화하는 DNA 서열 ; 및 (ii) DNA 서열의 발현을 유발하도록 위치한 프로모터를 함유하는 재조합 DNA 벡터로 진핵 숙주 세포를 형질전환시키고 ; (B) 단계 (A) 에서 형질전환된 숙주 세포를 DNA 서열의 발현을 허용하는 조건하에서 배양하는 단계를 포함함을 특징으로 하여, 진핵 숙주 세포로부터의 분비시 사람 단백질 C의 지모겐 형태의 재조합 생성 방법.상기 서열에서, R1은 PHE, GLY, TYR 또는 TRP이고, R2는 VAL 또는 PRO이며, R3는 ASP 또는 ASN이고, ARG는 아르기닌이며, ASN은 아스파라긴이고, ASP는 아스파르트산이며, -COOH는 카복시 말단이고, CYS는 시스테인이며, GLN은 글루타민이고, GLU는 글루탐산이며, GLY는 글리신이고, HIS는 히스티딘이며, ILE는 이소로이신이고, LEU는 로이신이며, LYS는 리진이고, MET는 메티오닌이며, PHE는 페닐알라닌이고, PRO는 프롤린이며, SER는 세린이고, THR는 트레오닌이며, TRP는 트립토판이고, TYR은 티로신이며, VAL은 발린이다.
- 제15항에 있어서, 재조합 DNA 발현 벡터가 플라스미드 pLPC-167F인 방법.
- 제15항에 있어서, 재조합 DNA 발현 벡터가 플라스미드 pLPC-167G인 방법.
- 제15항에 있어서, 숙주 세포가 293 또는 AV12숙주 세포인 방법.
- 제18항에 있어서, 단계(B)에서 배양된 숙주 세포가 293/pLPC-167F, 293/p-LPC-167G, AV12/pLPC-167F 또는 AV12/pLPC-167G 숙주 세포인 방법.
- 하기의 아미노산 잔기 서열을 갖는 단백질 C 지모겐.상기 서열에서, H2N은 아미노 말단이고, R1은 PHE, GLY, TYR 또는 TRP이며, R2는 VAL 또는 PRO이고, R3는 ASP 또는 ASN이며, ARG는 아르기닌이고, ASN은 아스파라긴이며, ASP는 아스파르트산이고, -COOH는 카복시 말단이며, CYS는 시스테인이고, GLN은 글루타민이며, GLU는 글루탐산이고, GLY는 글리신이며, HIS는 히스티딘이고, ILE는 이소로이신이며, LEU는 로이신이고, LYS는 리진이며, MET는 메티오닌이고, PHE는 페닐알라닌이며, PRO는 프롤린이고, SER는 세린이며, THR는 트레오닌이고, TRP는 트립토판이며, TYR은 티로신이고, VAL은 발린이다.
- 제20항에 있어서, R1이 PHE이고, R2가 PRO이며, R3가 ASP인 지모겐.
- 제20항에 있어서, R1이 GLY이고, R2가 PRO이며, R3가 ASP인 지모겐.
- 지혈 조절제로서의 제20항, 21항 또는 22항의 지모겐의 용도.
- 하기와 같은, 활성화된 사람 단백질 C의 경 쇄 및 중 쇄(heavy chain)를 함유함을 특징으로 하는 활성화된 단백질 C 분자.상기 서열에서, H2N-은 아미노 말단이고, ALA는 알라닌이며, ARG는 아르기닌이고, ASN은 아스파라긴이며, ASP는 아스파르트산이고, -COOH는 카복시-말단이며, CYS는 시스테인이고, GLN은 글루타민이며, GLU는 글루탐산이고, GLY는 글리신이며, HIS는 히스티딘이고, ILE는 이소로이신이며, LEU는 로이신이고, LYS는 리진이며, MET는 메티오닌이고, PHE는 페닐알라닌이며, PRO는 프롤린이고, SER는 세린이며, THR는 트레오닌이고, TRP는 트립토판이며, TYR은 티로신이고, VAL은 발린이다.
- 지혈 조절제로서의 제24항의 활성화된 단백질 C의 용도.
- 제20항의 지모겐을, 이를 위한 약제학적으로-허용가능한 담체와의 혼합물 형태로 함유함을 특징으로 하는 약제학적 제제.
- 제24항의 활성화된 단백질 C를, 이를 위한 약제학적으로-허용가능한 담체와의 혼합물 형태로 함유함을 특징으로 하는 약제학적 제제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13800987A | 1987-12-28 | 1987-12-28 | |
| US138,009 | 1987-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR890010202A true KR890010202A (ko) | 1989-08-07 |
Family
ID=22480037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880017552A Withdrawn KR890010202A (ko) | 1987-12-28 | 1988-12-27 | 사람 단백질 c의 지모겐 형태의 발현용 벡터 및 화합물 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0323149B1 (ko) |
| JP (1) | JP2851287B2 (ko) |
| KR (1) | KR890010202A (ko) |
| CN (1) | CN1035526A (ko) |
| AR (1) | AR244804A1 (ko) |
| AT (1) | ATE116368T1 (ko) |
| AU (1) | AU609919B2 (ko) |
| CA (1) | CA1340111C (ko) |
| DE (1) | DE3852625T2 (ko) |
| DK (1) | DK723488A (ko) |
| ES (1) | ES2065341T3 (ko) |
| GR (1) | GR3015609T3 (ko) |
| HU (1) | HU210863B (ko) |
| IE (1) | IE66337B1 (ko) |
| IL (1) | IL88758A (ko) |
| MX (1) | MX14312A (ko) |
| NZ (1) | NZ227434A (ko) |
| PT (1) | PT89285B (ko) |
| RU (1) | RU2018535C1 (ko) |
| SU (1) | SU1739854A3 (ko) |
| ZA (1) | ZA889497B (ko) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0380508A4 (en) * | 1987-05-18 | 1991-04-03 | Integrated Genetics, Inc. | Improved protein c molecules and method for making and activating same |
| US4992373A (en) * | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| US5358932A (en) * | 1989-12-29 | 1994-10-25 | Zymogenetics, Inc. | Hybrid protein C |
| JP3270462B2 (ja) * | 1989-12-29 | 2002-04-02 | ザイモジェネティクス，インコーポレイティド | ハイブリッドプロテインｃ |
| US5270178A (en) * | 1990-02-23 | 1993-12-14 | Eli Lilly And Company | Vectors and compounds for expression of zymogen forms of human protein C |
| IL97311A0 (en) * | 1990-02-23 | 1992-05-25 | Lilly Co Eli | Vectors and compounds for expression of glycosylation mutants of human protein c |
| MY110664A (en) * | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| US5618714A (en) * | 1993-12-15 | 1997-04-08 | Eli Lilly And Company | Methods for producing protein C |
| RU2214833C2 (ru) * | 1994-10-24 | 2003-10-27 | Ново Нордиск Хелс Кеар Аг | Модифицированный фактор vii |
| EP1237917A2 (en) * | 1999-11-19 | 2002-09-11 | Eli Lilly And Company | Protein c derivatives |
| BRPI0514396A2 (pt) * | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | polipeptìdeos dependentes de vitamina k modificada |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
-
1988
- 1988-12-20 ZA ZA889497A patent/ZA889497B/xx unknown
- 1988-12-21 NZ NZ227434A patent/NZ227434A/en unknown
- 1988-12-21 PT PT89285A patent/PT89285B/pt not_active IP Right Cessation
- 1988-12-21 IL IL8875888A patent/IL88758A/en not_active IP Right Cessation
- 1988-12-21 AU AU27329/88A patent/AU609919B2/en not_active Ceased
- 1988-12-22 IE IE384988A patent/IE66337B1/en not_active IP Right Cessation
- 1988-12-22 ES ES88312201T patent/ES2065341T3/es not_active Expired - Lifetime
- 1988-12-22 EP EP88312201A patent/EP0323149B1/en not_active Expired - Lifetime
- 1988-12-22 MX MX1431288A patent/MX14312A/es unknown
- 1988-12-22 AT AT88312201T patent/ATE116368T1/de not_active IP Right Cessation
- 1988-12-22 SU SU884613143A patent/SU1739854A3/ru active
- 1988-12-22 AR AR88312838A patent/AR244804A1/es active
- 1988-12-22 DE DE3852625T patent/DE3852625T2/de not_active Expired - Fee Related
- 1988-12-22 HU HU886577A patent/HU210863B/hu not_active IP Right Cessation
- 1988-12-23 CA CA000587009A patent/CA1340111C/en not_active Expired - Fee Related
- 1988-12-24 CN CN88105199A patent/CN1035526A/zh active Pending
- 1988-12-27 KR KR1019880017552A patent/KR890010202A/ko not_active Withdrawn
- 1988-12-27 JP JP63332757A patent/JP2851287B2/ja not_active Expired - Lifetime
- 1988-12-27 DK DK723488A patent/DK723488A/da not_active Application Discontinuation
-
1989
- 1989-11-14 RU SU894742440A patent/RU2018535C1/ru active
-
1995
- 1995-03-23 GR GR950400685T patent/GR3015609T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2065341T3 (es) | 1995-02-16 |
| JP2851287B2 (ja) | 1999-01-27 |
| EP0323149A2 (en) | 1989-07-05 |
| GR3015609T3 (en) | 1995-06-30 |
| IE883849L (en) | 1989-06-28 |
| ZA889497B (en) | 1990-08-29 |
| DE3852625D1 (de) | 1995-02-09 |
| AU2732988A (en) | 1989-06-29 |
| DK723488D0 (da) | 1988-12-27 |
| CA1340111C (en) | 1998-11-03 |
| CN1035526A (zh) | 1989-09-13 |
| NZ227434A (en) | 1991-03-26 |
| DK723488A (da) | 1989-06-29 |
| IE66337B1 (en) | 1995-12-27 |
| IL88758A0 (en) | 1989-07-31 |
| AU609919B2 (en) | 1991-05-09 |
| JPH022376A (ja) | 1990-01-08 |
| EP0323149B1 (en) | 1994-12-28 |
| IL88758A (en) | 1994-02-27 |
| SU1739854A3 (ru) | 1992-06-07 |
| EP0323149A3 (en) | 1990-06-13 |
| HUT50499A (en) | 1990-02-28 |
| DE3852625T2 (de) | 1995-05-24 |
| PT89285A (pt) | 1989-12-29 |
| PT89285B (pt) | 1993-08-31 |
| MX14312A (es) | 1994-01-31 |
| HU210863B (en) | 1995-08-28 |
| RU2018535C1 (ru) | 1994-08-30 |
| ATE116368T1 (de) | 1995-01-15 |
| AR244804A1 (es) | 1993-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890010199A (ko) | 활성화된 사람의 단백질 c의 직접 발현용 벡터 및 화합물 | |
| Kemp et al. | Synthetic hexapeptide substrates and inhibitors of 3': 5'-cyclic AMP-dependent protein kinase. | |
| Martenson et al. | Differences between the two myelin basic proteins of the rat central nervous system: a deletion in the smaller protein | |
| Han et al. | The covalent structure of beef heart myoglobin | |
| DE69011853D1 (de) | System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet. | |
| ATE68014T1 (de) | Die synthese eines proteins mittels eines identifizierungspeptids. | |
| DE112006000677A5 (de) | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form | |
| ES2052791T3 (es) | Nuevos peptidos señal capaces de funcionar en levaduras, y expresion secretora de proteinas heterologas que utilizan los mismos. | |
| TAKAHASHI et al. | Snake venom proteinase inhibitors: II. Chemical structure of inhibitor II isolated from the venom of Russell's viper (Vipera russelli) | |
| ES2112255T3 (es) | Complejos proteicos que tienen actividad del factor viii:c y su produccion. | |
| AU5963290A (en) | Inhibition of the n-end rule pathway in living cells | |
| Louvard et al. | On bovine and porcine anionic trypsinogens | |
| KR870000428A (ko) | 인체혈청 알부민의 제조방법 | |
| Raulais et al. | The complete amino‐acid sequence of rat thyrocalcitonin | |
| Huang et al. | Egg White Avidin: II. ISOLATION, COMPOSITION, AND AMINO ACID SEQUENCES OF THE TRYPTIC PEPTIDES | |
| Sairam et al. | The primary structure of ovine interstitial cell-stimulating hormone: II. The β-subunit | |
| Lee et al. | Does carboxypeptidase Y have intrinsic endopeptidase activity? | |
| KR860008287A (ko) | 이소 페니실린 n 합성효소를 코드화하는 dna 화합물 및 재조합 dna 발현 벡터 | |
| McClintock et al. | Two distinct pathways of the streptokinase-mediated activation of highly purified human plasminogen | |
| Chan et al. | Amino acid sequence of chicken heart cytochrome c | |
| Elleman et al. | The sequence of SCMK-B2B, a high-sulfur protein from wool keratin | |
| Møyner et al. | An unusually large (83 amino acid residues) amyloid fibril protein AA from a patient with Waldenström's macroglobulinaemia and amyloidosis | |
| Canova-Davis et al. | Characterization of chemically synthesized human relaxin by high-performance liquid chromatography | |
| EP0195680A3 (en) | The synthesis of protein with an identification peptide | |
| Hayashi et al. | Amino acid sequence of cardiotoxin-analogue I from the venom of Naja naja atra |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19881227 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |